new_0222_0423|CYT|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
new_0222_0423|CYT|Long Name|1|1|Cyteir Therapeutics Inc Total Current Assets (Quarterly) (USD)|Cyteir Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Cyteir Therapeutics Inc Inventories (Quarterly) (USD)|Cyteir Therapeutics Inc Net PP&E (Quarterly) (USD)|Cyteir Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Cyteir Therapeutics Inc Total Liabilities (Quarterly) (USD)|Cyteir Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Cyteir Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Cyteir Therapeutics Inc Total Deposits (Quarterly) (USD)|Cyteir Therapeutics Inc Book Value (Quarterly) (USD)|Cyteir Therapeutics Inc Retained Earnings (Quarterly) (USD)|Cyteir Therapeutics Inc Treasury Stock (Quarterly) (USD)|Cyteir Therapeutics Inc EV to Revenues|Cyteir Therapeutics Inc EV to Earnings|Cyteir Therapeutics Inc EV to Free Cash Flow|Cyteir Therapeutics Inc EV to Assets (Quarterly)|Cyteir Therapeutics Inc PS Ratio|Cyteir Therapeutics Inc PE Ratio|Cyteir Therapeutics Inc Price to Book Value|Cyteir Therapeutics Inc PEG Ratio|Cyteir Therapeutics Inc Debt to Equity Ratio|Cyteir Therapeutics Inc Dividend Yield|Cyteir Therapeutics Inc Shareholder Yield (TTM)|Cyteir Therapeutics Inc Percent of Shares Outstanding Short|Cyteir Therapeutics Inc Total Receivables (Quarterly) (USD)|Cyteir Therapeutics Inc Total Payables (Quarterly) (USD)|Cyteir Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Cyteir Therapeutics Inc Return on Invested Capital|Cyteir Therapeutics Inc Quality Ratio Score|Cyteir Therapeutics Inc Momentum Score|Cyteir Therapeutics Inc Beta (1Y)|Cyteir Therapeutics Inc Sustainable Growth Rate (TTM)|Cyteir Therapeutics Inc Institutional Investor Ownership Percentage|Cyteir Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Cyteir Therapeutics Inc Total Employees (Annual)|Cyteir Therapeutics Inc EPS Diluted (Quarterly) (USD)|Cyteir Therapeutics Inc Shares Outstanding|Cyteir Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Cyteir Therapeutics Inc Ordinary Shares Number (Quarterly)|Cyteir Therapeutics Inc Payout Ratio|Cyteir Therapeutics Inc Quick Ratio (Quarterly)|Cyteir Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Cyteir Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Cyteir Therapeutics Inc Effective Tax Rate (TTM)|Cyteir Therapeutics Inc Return on Equity|Cyteir Therapeutics Inc Net Income (TTM) (USD)|Cyteir Therapeutics Inc Revenue (TTM) (USD)|Cyteir Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Cyteir Therapeutics Inc Revenue (Quarterly) (USD)|Cyteir Therapeutics Inc Gross Profit (Quarterly) (USD)|Cyteir Therapeutics Inc SG&A Expense (Quarterly) (USD)|Cyteir Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Cyteir Therapeutics Inc Net Income (Quarterly) (USD)|Cyteir Therapeutics Inc Net Interest Income (Quarterly) (USD)|Cyteir Therapeutics Inc Price (USD)|Cyteir Therapeutics Inc Total Return Price (USD)|Cyteir Therapeutics Inc Enterprise Value (USD)|Cyteir Therapeutics Inc 30-Day Average Daily Volume|Cyteir Therapeutics Inc 1 Year Price Returns (Daily)
new_0222_0423|CYT|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
new_0222_0423|CYT||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly
new_0222_0423|CYT||5|5|91|91|0|91|0|91|91|91|0|91|91|0|0|0|1.44242424242|0|0|0|1.43949044586|0|0|1.44242424242|0|15.3571428571|90|91|91|0|0|0|0|0|31|91.3333333333|0|91.3333333333|29.8|0|91|0|0|91.3333333333|91.4|0|0|91|0|0|0|0|91.3333333333|91.3333333333|91.3333333333|0|1.44242424242|1.44242424242|1.44242424242|1.44117647059|0
new_0222_0423|CYT||6|6|3|3|0|3|0|3|3|3|0|3|3|0|0|0|165|0|0|0|157|0|0|165|0|14|1|3|3|0|0|0|0|0|2|6|0|6|5|0|3|0|0|6|5|0|0|3|0|0|0|0|6|6|6|0|165|165|165|136|0
new_0222_0423|CYT||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
new_0222_0423|CYT|202003|202003|202003||||||||||||||||||||||||||||||||||23.8903||-0.2482||||||-0.2482|||||||||1.009|-5.929|-5.929||||||
new_0222_0423|CYT|202006|202006|202006||||||||||||||||||||||||||||||||||23.8903||-0.1883||||||-0.1883|0||||||||0.875|-4.498|-4.498||||||
new_0222_0423|CYT|202009|202009|202009||||||||||||||||||||||||||||||||||23.8903||-0.2108||||||-0.2108|0||||||||0.831|-5.036|-5.036||||||
new_0222_0423|CYT|202012|202012|202012|12.131|10.938||1.287||61.766|3.137|58.629||-48.031|-49.927||||||||||||||0.063|1.689|0.002|||||||23.8903||-0.2244|||34.4666|||-0.2244||||-20.823|||||1.463|-5.36|-5.36||||||
new_0222_0423|CYT|202103|202103|202103|85.385|84.195||1.432||142.293|4.264|138.029||-54.504|-57.239||||||||||||||0.059|2.805|0.002|||||||23.8903||-0.31|||34.4666|||-0.31||||-22.206|||||1.724|-7.312|-7.312||||||
new_0222_0423|CYT|202105|202103|202103|||||||||||||||||||||||||||||||||||31||||||||||||||||||||||||
new_0222_0423|CYT|202106|202106|202106|200.305|198.637||1.492||8.198|7.444|0.754||193.855|-68.534||||-22.3019||||3.7649|||0||0.0931||3.512|0.034||||||78.4356|2.3379||-4.83|34.1049||34.1049|||-4.83|-121.627|||-29.003|||||2.422|-11.295|-11.295||21.4|21.4|531.2079||
new_0222_0423|CYT|202107|202106|202106|||||||||||||||-19.2234||||3.3867|||0||1.8792|||||||||81.8364||||||||||||||||||||||19.25|19.25|457.8823|201293.4|
new_0222_0423|CYT|202108|202106|202106|||||||||||||||-19.9932||||3.4812|||0||3.751|||||||||80.8225||||35.3697||||||||||||||||||19.08|19.08|476.2169|109650.2333|
new_0222_0423|CYT|202109|202109|202109|204.219|199.822||1.634||8.267|7.53|0.737||197.842|-80.238||||-12.8859||||3.1141|||0||6.9471||3.276|0.035|||||||35.0629||-0.33|35.1055||35.1055|||-0.33|-14.494|||-35.671|||||3.547|-11.704|-11.704||17.55|17.55|416.2795|184291.8|
new_0222_0423|CYT|202110|202109|202109|||||||||||||||-13.2771||||3.178|||0||6.0209|||||||||||||||||||||||||||||||17.91|17.91|428.9175|83737.9|
new_0222_0423|CYT|202111|202109|202109|||||||||||||||-12.0009||||2.9696|||0||6.3703|||||||||||||35.3709||||||||||||||||||16.61|16.61|387.6886|62278.2|
new_0222_0423|CYT|202112|202112|202112|||||||||||||||-6.2636||||2.0328|||0||6.75|||||||||||||||||||||||||||||||11.37|11.37|202.3451|73488.2667|
new_0222_0423|CYT|202201|202112|202112|||||||||||||||-0.4715||||1.087|||0||7.0454|||||||||||||||||||||||||||||||6.08|6.08|15.2331|124069.3667|
new_0222_0423|CYT|202202|202112|202112|||||||||||||||-0.6029||||1.1085|||0|||||||||||||||||||||||||||||||||6.2|6.2|19.4776|126996.2333|